N
2.95
-0.08 (-2.64%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | NRX Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
2.4
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 2.38 |
|
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 15.88% |
| 机构持股比例 | 13.34% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| One Wealth Management Investment & Advisory Services, Llc | 31 Dec 2025 | 37,873 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 45.00 (HC Wainwright & Co., 1,425.42%) | 购买 |
| 中 | 39.50 (1,238.98%) | |
| 低 | 34.00 (D. Boral Capital, 1,052.54%) | 购买 |
| 平均值 | 39.50 (1,238.98%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 1.77 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 09 Mar 2026 | 34.00 (1,052.54%) | 购买 | 1.73 |
| HC Wainwright & Co. | 03 Mar 2026 | 45.00 (1,425.42%) | 购买 | 1.80 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合